NCT02753881View on ClinicalTrials.gov

Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Liver Cancer
Interventions
DRUG

whole liver lobe cTACE doxorubicin

Doxorubicin CTACE administered in a whole liver lobe manner.

DRUG

superselective cTACE doxorubicin

Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.

Trial Locations (1)

06520

Yale University, Department of Diagnostic Radiology, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02753881 - Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer | Biotech Hunter | Biotech Hunter